Revealing the Potential of Mucoadhesive Ocular Nanoparticles for Enhanced Drug Delivery

Abstract

An ocular drug delivery system, or ODDS, is the method for executing a prescription to the peeper in order to treat or manage conditions related to the eyes. The range of ODDS modalities is broad and includes simple aseptic eye drops for the optic surface as well as complex implants for intraocular tissue. The use of ODDS is often necessary for states such as cataracts, progressive retinal illness, inflammation, dry eye syndrome, diabetic retinopathy (DR), and other related diseases or disorders. To sustain the intended drug concentrations at the prescribed place, new drug delivery technologies have been developed, incorporating fibrin-sealing materials and sticky gels. The advancement of long-lasting drug delivery systems that are non-invasive and applied externally to the back portion of the eye possesses the potential to improve drug administration significantly. The progress made in the field of ophthalmic drug delivery has resulted in promising advancements in the treatment of diseases affecting both the front and back portions of the eye. These groundbreaking strategies for administering medication hold immense potential for enhancing drug delivery in the future. Furthermore, these inventive devices and/or formulations are easy to develop, causing minimal or negligible irritation, boasting a prolonged period residing in front of the cornea, sustaining the release of drugs, and increasing the therapeutic availability of medications within the eye. To remain up to date with the current advancements in the field of ocular drug delivery, it is essential to acquire the latest information. This helps drug delivery scientists improve their thought processes and also makes it possible to create fresh, trustworthy drug delivery methods. The objective of this investigation is to provide a thorough investigation while also tracking their advancement. Next, we shall examine the latest breakthroughs in formulation innovations based on nanotechnology. We will also discuss the most recent developments in additional ocular medication administration methods, including in-situ gels, implants, contact lenses, and microneedles.